此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Low-Level Laser Therapy Versus Isometric Handgrip Exercise On Arteriovenous Fistula Maturation in Hemodialysis Patients

2026年8月24日 更新者:Muhammad Atef Ibrahim、Cairo University
The purpose of this study is to evaluate the effectiveness of low-level laser therapy (LLLT) compared with isometric handgrip exercise and standard care in promoting vascular remodeling of arteriovenous fistulas (AVFs) among hemodialysis patients.

研究概览

详细说明

Hemodialysis remains a life-sustaining therapy for patients with end-stage renal disease, and the creation of a reliable arteriovenous fistula (AVF) is considered the gold standard for vascular access. However, despite its clinical advantages, AVF maturation failure occurs in up to 40% of patients, often due to inadequate vein dilation or early stenosis. Such shortcomings can delay dialysis initiation, increase the need for central venous catheters, and heighten the risk of infection and hospitalization. Interventions that can support or accelerate vascular remodeling and improve AVF usability, therefore, remain a significant focus in nephrology and vascular research.

Several strategies have been investigated to enhance AVF maturation, including surgical modifications, pharmacological therapies, and rehabilitative interventions. Among conservative methods, isometric handgrip exercise has shown promise by improving venous return, stimulating shear stress, and promoting dilation of the access vein. More recently, low-level laser therapy (LLLT) has gained attention for its ability to modulate endothelial function, stimulate nitric oxide release, and improve microcirculation, with preliminary evidence suggesting beneficial effects on vascular tone and tissue healing. Nevertheless, comparative data between exercise-based and photobiomodulation-based approaches remain limited.

This study is significant because it directly compares two non-invasive interventions-LLLT and isometric handgrip exercise-for their ability to enhance the vascular diameter of AVFs in hemodialysis patients. By clarifying whether photobiomodulation offers comparable or superior outcomes to exercise, the findings may help guide clinicians in selecting effective, patient-appropriate strategies to optimize AVF maturation and long-term patency. Ultimately, this research addresses a critical gap in vascular access management and may contribute to reducing access-related complications, improving dialysis efficiency, and enhancing the quality of life for patients dependent on chronic hemodialysis.

To our knowledge, this is the first randomized controlled trial to evaluate extravascular low-level laser therapy head-to-head with isometric handgrip exercise for promoting radiocephalic arteriovenous fistula maturation in patients with chronic kidney disease.

研究类型

介入性

注册 (估计的)

75

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Hend A Abdel Monaem, PHD
  • 电话号码:01115507195
  • 邮箱:Drhendpt@cu.edu.eg

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  • Patients of both genders.
  • Patient age between 35 and 50 years.
  • Diagnosed with chronic kidney disease (CKD) Stage 4 or 5 with a newly created radiocephalic arteriovenous fistula (RC-AVF), including both pre-dialysis patients and those temporarily receiving hemodialysis via central venous catheter pending fistula maturation.
  • Distal forearm cephalic vein diameter ≥ 2.5 mm in the non-dominant hand

Exclusion Criteria:

  • History of prior vascular access surgery on the same limb.
  • Physical or mental disability limiting the ability to perform exercises.
  • Positive Allen's test.
  • Absent or thrombosed distal forearm cephalic vein.
  • Already undergoing regular exercise (including manual workers).
  • History of hemophilia or known coagulation disorder.
  • Personal or family history of cancer.
  • Severe cardiac disease (congestive heart failure with ejection fraction ≤ 20%).
  • Known central venous stenosis > 50% on the side of planned arteriovenous fistula creation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Low-level laser therapy group
Patients received extravascular low-level laser therapy (LLLT) in the form of a laser watch device applied just above the wrist joint, three sessions weekly for 8 weeks.
Patients in this group will receive low-level laser therapy using the BS-W11 semiconductor low-level laser device, which emitted a red laser at 650 nm with a power output of 5 mW per diode. The laser will be applied over the arteriovenous fistula site. Each session lasts 30 minutes and is administered three times a week for a total period of eight consecutive weeks. A trained therapist will perform all procedures, and patients were monitored for any potential adverse reactions during and after each session.
实验性的:Isometric Handgrip Exercise group
Patients performed isometric handgrip exercise using a calibrated handgrip dynamometer/squeeze ball daily for 8 weeks.
Patients will be instructed to perform daily isometric handgrip exercises using a standard squeeze ball. Patients will be positioned seated comfortably, with the forearm of the exercising limb resting on the ipsilateral thigh and the elbow maintained in slight flexion throughout the exercise, in order to minimize compensatory shoulder and elbow movement and ensure that the contraction remained isolated to the forearm muscles. The exercise protocol involves squeezing at a rate of approximately 20 squeezes per minute for a total of 30 minutes per day, at 30-40% of maximum voluntary contraction (MVC). To improve compliance, participants will be allowed to divide the daily session into two 15-minute intervals if required. The exercise program continued for 8 consecutive weeks, and patients will be instructed to maintain adherence by recording their daily sessions in a logbook
有源比较器:Standard postoperative care
Patients will receive standard postoperative care only, with no additional intervention.
It includes wound and dressing management (keeping the dressing dry for the initial 48-72 hours, followed by regular dressing changes and site hygiene), activity restriction (avoiding heavy lifting or direct pressure over the access site during the early postoperative period), patient education on self-palpation of the access thrill, and routine follow-up visits at approximately 1 week and 6 weeks postoperatively to assess wound healing and access patency.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Average Vein Diameter
大体时间:8 weeks
It will be measured by the doppler ultrasound. The internal luminal diameter of the arteriovenous fistula (cephalic vein), measured in millimeters (mm) by duplex ultrasound at a standardized point along the fistula tract, typically 5-10 cm proximal to the anastomosis, with the patient in a seated or semi-recumbent position and a tourniquet applied to standardize venous filling. A diameter ≥6 mm is generally considered indicative of adequate fistula maturation.
8 weeks
Rate of blood flow
大体时间:8 weeks

It will me measured by the doppler ultrasound. The volumetric rate of blood flow through the arteriovenous fistula, measured in milliliters per minute (mL/min) using duplex ultrasound Doppler assessment at a standardized site along the fistula outflow vein. Access flow is calculated from the vessel cross-sectional area and the time-averaged mean velocity (TAMV), as follows:

Access Flow (Qa) = π × (D / 2)2 × TAMV × 60 where D = vein diameter (cm), TAMV = time-averaged mean velocity (cm/s), and 60 converts cm³/s to mL/min.

A flow rate >600 mL/min is generally considered indicative of adequate fistula maturation.

8 weeks
Time-Averaged Mean Velocity (TAMV)
大体时间:8 weeks
The mean blood flow velocity within the fistula vein, averaged over the complete cardiac cycle, obtained by pulsed-wave Doppler ultrasound.. TAMV is expressed in centimeters per second (cm/s) and is used, together with the vessel cross-sectional area, to derive access flow.
8 weeks
Maturation of arteriovenous fistulas
大体时间:8 weeks
It will be evaluated by duplex ultrasound at 8 weeks post-creation by a vascular sonographer. A composite clinical outcome indicating that the arteriovenous fistula has developed sufficient diameter, blood flow, and depth to permit successful and sustained cannulation for hemodialysis. Maturation is assessed at a predefined postoperative time point by duplex ultrasound against standardized criteria - vein diameter ≥6 mm, access flow >600 mL/min, and depth from the skin surface ≤6 mm - in conjunction with documented successful two-needle cannulation for dialysis.
8 weeks

次要结果测量

结果测量
措施说明
大体时间
Pain intensity level
大体时间:8 weeks
Pain intensity will be measured by applying the visual analogue scale (VAS). The VAS is a 100-mm horizontal line, with one end defined as no pain (0 mm) and the other as worst imaginable pain (100 mm). Each participant will be asked to mark a point on the line corresponding to their level of pain at the arteriovenous fistula site. This procedure will be repeated three times, and the average will be recorded
8 weeks
Kidney disease-related quality of life (KDQOL-36™)
大体时间:8 weeks
The KDQOL-36™ will be used to assess health-related quality of life in patients with chronic kidney disease referred for hemodialysis vascular access. It is a validated, self-administered questionnaire that combines a generic core health survey with kidney-disease-targeted items, covering physical and mental health domains as well as burden of kidney disease, symptoms/problems, and effects of kidney disease on daily life. Higher scores reflect a better perceived quality of life.
8 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Mohamed F Radwan、Ain Shams University
  • 学习椅:Hany E Obya, Professor、Cairo University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2027年3月15日

研究完成 (估计的)

2027年3月31日

研究注册日期

首次提交

2026年8月24日

首先提交符合 QC 标准的

2026年8月24日

首次发布 (实际的)

2026年8月26日

研究记录更新

最后更新发布 (实际的)

2026年8月26日

上次提交的符合 QC 标准的更新

2026年8月24日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • P.T.REC/012/006425

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅